Last reviewed · How we verify

Metformin / alogliptin Oral Product

University of Catanzaro · FDA-approved active Small molecule

Metformin / alogliptin Oral Product is a Biguanide / DPP-4 inhibitor combination Small molecule drug developed by University of Catanzaro. It is currently FDA-approved for Type 2 diabetes mellitus.

Metformin reduces hepatic glucose production and improves insulin sensitivity, while alogliptin inhibits DPP-4 to increase incretin levels and stimulate insulin secretion in response to glucose.

Metformin reduces hepatic glucose production and improves insulin sensitivity, while alogliptin inhibits DPP-4 to increase incretin levels and stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.

At a glance

Generic nameMetformin / alogliptin Oral Product
SponsorUniversity of Catanzaro
Drug classBiguanide / DPP-4 inhibitor combination
TargetMetformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Metformin is a biguanide that decreases gluconeogenesis and enhances peripheral glucose uptake, primarily in muscle and adipose tissue. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the degradation of GLP-1 and GIP, thereby prolonging their action to stimulate glucose-dependent insulin secretion and suppress glucagon. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metformin / alogliptin Oral Product

What is Metformin / alogliptin Oral Product?

Metformin / alogliptin Oral Product is a Biguanide / DPP-4 inhibitor combination drug developed by University of Catanzaro, indicated for Type 2 diabetes mellitus.

How does Metformin / alogliptin Oral Product work?

Metformin reduces hepatic glucose production and improves insulin sensitivity, while alogliptin inhibits DPP-4 to increase incretin levels and stimulate insulin secretion in response to glucose.

What is Metformin / alogliptin Oral Product used for?

Metformin / alogliptin Oral Product is indicated for Type 2 diabetes mellitus.

Who makes Metformin / alogliptin Oral Product?

Metformin / alogliptin Oral Product is developed and marketed by University of Catanzaro (see full University of Catanzaro pipeline at /company/university-of-catanzaro).

What drug class is Metformin / alogliptin Oral Product in?

Metformin / alogliptin Oral Product belongs to the Biguanide / DPP-4 inhibitor combination class. See all Biguanide / DPP-4 inhibitor combination drugs at /class/biguanide-dpp-4-inhibitor-combination.

What development phase is Metformin / alogliptin Oral Product in?

Metformin / alogliptin Oral Product is FDA-approved (marketed).

What are the side effects of Metformin / alogliptin Oral Product?

Common side effects of Metformin / alogliptin Oral Product include Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort), Hypoglycemia, Headache, Nasopharyngitis, Lactic acidosis (rare, metformin-related).

What does Metformin / alogliptin Oral Product target?

Metformin / alogliptin Oral Product targets Metformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4) and is a Biguanide / DPP-4 inhibitor combination.

Related